KJ-C2111

N/A

Report date: 2025/04/30 14:59:32

Base Information

Drug NameKJ-C2111
Drug Alias NameKJ-C2111CT-0590
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein inhibitorsT lymphocyte replacements
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaLeukemia, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCARsgen Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYoukaize Biopharmaceutical (Shanghai) Co LtdCARsgen Therapeutics Holdings LtdCarsgen Biomedicine (Shanghai) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A